Answers are grounded in this paper and cite their sources.
Neurodegeneration with brain iron accumulation (NBIA) is a broad, heterogeneous group of rare inherited diseases (1–3 patients/1,000,000 people) characterized by progressive symptoms associated with excessive abnormal iron deposition in the brain. Approximately 15,000–20,000 individuals worldwide are estimated to be affected by NBIA. NBIA is usually associated with slowly progressive pyramidal and extrapyramidal symptoms, axonal motor neuropathy, optic nerve atrophy, cognitive impairment and neuropsychiatric disorders. To date, eleven subtypes of NBIA have been described and the most common ones include pantothenate kinase-associated neurodegeneration (PKAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN) and beta-propeller protein-associated neurodegeneration (BPAN). We present a comprehensive overview of the evidence for disturbed cellular homeostasis and metabolic alterations in NBIA variants, with a careful focus on mitochondrial bioenergetics and lipid metabolism which drives a new perspective in understanding the course of this infrequent malady. • The complexity of NBIA is determined by mutations in 16 genes. • 16 mutations are responsible for the development of 11 NBIA subtypes. • Relationship between Fe accumulation and NBIA symptoms is still far from clear. • The role of metabolic dysfunction in the pathogenesis of NBIA is still unclear. • There is wild spectrum of metabolic dysfunction in the individual NBIA subtypes.
No takes yet. Share an insight, caveat, or question.
Wydrych et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: